Article
Oncology
Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers, Adam M. Brufksy, Simon H. Waters, Sara A. Hurvitz, Beverly Moy, Sung-Bae Kim, William J. Gradishar, Geraldo Silva Queiroz, Eduardo Cronemberger, Gerald J. Wallweber, Judith Bebchuk, Kiana Keyvanjah, Alshad S. Lalani, Richard Bryce, Ana Vivancos, Lisa D. Eli, Suzette Delaloge
Summary: PIK3CA mutations were associated with shorter PFS, while higher HER2 expression was associated with longer PFS. Higher HER2 protein expression was also associated with a greater benefit for N+C compared with L+C.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Fangfang Duan, Muyi Zhong, Yuyu Ma, Chenge Song, Lehong Zhang, Ying Lin, Zhiyong Wu, Yuanqi Zhang, Jiajia Huang, Fei Xu, Yanxia Shi, Shusen Wang, Zhongyu Yuan, Wen Xia, Xiwen Bi
Summary: The switching mode showed superior efficacy compared to continuing mode in subsequent anti-HER2 therapy for patients with HER2-positive refractory metastatic breast cancer.
Article
Oncology
Jens Huober, Carlos H. Barrios, Naoki Niikura, Michal Jarzab, Yuan-Ching Chang, Shannon L. Huggins-Puhalla, Jose Pedrini, Lyudmila Zhukova, Vilma Graupner, Daniel Eiger, Volkmar Henschel, Nino Gochitashvili, Chiara Lambertini, Eleonora Restuccia, Hong Zhang
Summary: This study investigated the efficacy of combining atezolizumab with chemotherapy in high-risk, HER2-positive early breast cancer patients. Results showed that atezolizumab did not increase pCR rates in either the ITT or PD-L1-positive populations, and more adverse events were seen in the atezolizumab group. Therefore, PH and chemotherapy remain the standard of care for these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Medicine, General & Internal
Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li
Summary: This study compared the efficacy of trastuzumab plus lapatinib therapy versus standard trastuzumab therapy in HER2-positive breast cancer patients. The results showed that trastuzumab combined with lapatinib therapy was superior in overall survival, disease-free survival, and pathologic complete response, but had more non-cardiac grade III/IV toxicities. Lapatinib therapy was inferior to standard trastuzumab therapy in terms of efficacy.
SYSTEMATIC REVIEWS
(2022)
Article
Oncology
Ian E. Krop, Seock-Ah Im, Carlos Barrios, Herve Bonnefoi, Julie Gralow, Masakazu Toi, Paul A. Ellis, Luca Gianni, Sandra M. Swain, Young-Hyuck Im, Michelino De Laurentiis, Zbigniew Nowecki, Chiun-Sheng Huang, Louis Fehrenbacher, Yoshinori Ito, Jigna Shah, Thomas Boulet, Haiying Liu, Harrison Macharia, Peter Trask, Chunyan Song, Eric P. Winer, Nadia Harbeck
Summary: The purpose of this study was to improve the treatment of high-risk HER2-positive early breast cancer by replacing taxanes and trastuzumab with T-DM1. The study found that there was no significant difference in disease-free survival between the two treatment arms, but the T-DM1 group had a lower treatment completion rate.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Marion van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Charles E. Geyer, Luca Gianni, Andreas Schneeweiss, Pierfranco Conte, Martine Piccart, Herve Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Colin Neate, Richard Gelber, Coralie Poncet, Pierre Squifflet, Everardo D. Saad, Dominik Heinzmann, Carsten Denkert, Priya Rastogi, Javier Cortes, Valentina Guarneri, Evandro de Azambuja, David Cameron, Gustavo Ismael, Norman Wolmark, Patricia Cortazar
Summary: Achieving pCR is important for the prognosis of EFS and OS in patients with early breast cancer. This study investigates prognostic factors for EFS and OS in patients with and without pCR after neoadjuvant therapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Francesca Ligorio, Giovanni Fuca, Emma Zattarin, Riccardo Lobefaro, Luca Zambelli, Rita Leporati, Carmen Rea, Gabriella Mariani, Giulia V. Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri
Summary: The Pan-Immune-Inflammatory Value (PIV) in peripheral blood may serve as a new and powerful predictor of overall survival in HER2+ advanced breast cancer patients treated with first-line trastuzumab-pertuzumab-containing biochemotherapy, potentially improving prognostic stratification in this patient population.
Article
Oncology
Hye Ryeon Kim, Soomin Ahn, Hyunji Jo, Hongsik Kim, Joohyun Hong, Jeeyun Lee, Ho-Yeong Lim, Won Ki Kang, Seung Tae Kim
Summary: Trastuzumab plus chemotherapy as first-line therapy for HER2-positive AGC patients showed a favorable trend in those with high TMB, suggesting TMB could be a novel biomarker for predicting treatment efficacy in this population.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Joseph Gligorov, Xavier Pivot, Beyhan Ataseven, Michelino De Laurentiis, Kyung Hae Jung, Alexey Manikhas, Hamdy Abdel Azim, Kushagra Gupta, Ari Alexandrou, Luis Herraez-Baranda, Nadia Tosti, Eleonora Restuccia
Summary: The 5-year follow-up of the SafeHER Phase III study showed that subcutaneous trastuzumab is safe and effective for HER2-positive early breast cancer treatment, with no new safety signals observed and majority of adverse events being grade 1 or 2. Disease-free survival rates varied among different chemotherapy subgroups.
Article
Oncology
D. Miles, E. Ciruelos, A. Schneeweiss, F. Puglisi, T. Peretz-Yablonski, M. Campone, I. Bondarenko, Z. Nowecki, H. Errihani, S. Paluch-Shimon, A. Wardley, J. -l. Merot, P. Trask, Y. du Toit, C. Pena-Murillo, V. Revelant, D. Klingbiel, T. Bachelot
Summary: The combination of pertuzumab and trastuzumab with investigator-selected taxane in the treatment for HER2-positive LR/mBC shows consistent safety and efficacy compared to previous studies. Exploratory analyses suggest potential risk factors that may influence treatment outcomes.
ANNALS OF ONCOLOGY
(2021)
Review
Oncology
Sonia Pernas, Sara M. Tolaney
Summary: The addition of trastuzumab to chemotherapy has significantly improved the prognosis of early-stage HER2-positive breast cancer, but disease recurrence still remains a challenge. Advances in understanding tumor biology have led to the development of optimized anti-HER2 drugs and strategies to further enhance survival outcomes. Recurrences in the brain, biological heterogeneity within HER2-positive disease, and the need to personalize treatment strategies based on biomarkers are key considerations in the management of early-stage, HER2-positive breast cancer.
JCO ONCOLOGY PRACTICE
(2021)
Article
Oncology
Min Yan, Quchang Ouyang, Tao Sun, Limin Niu, Jin Yang, Li Li, Yuhua Song, Chunfang Hao, Zhanhong Chen, Armando Orlandi, Naohiro Ishii, Kazuaki Takabe, Gianluca Franceschini, Francesco Ricci, Claire Verschraegen, Zhenzhen Liu, Mengwei Zhang, Huimin Lv, Liping Liu, Xiaohong Yang, Huawu Xiao, Zhichao Gao, Xiaorui Li, Fangyuan Dong, Xiuchun Chen, Jianghua Qiao, Guifang Zhang
Summary: This study investigated the activity and safety of pyrotinib plus capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases. The combination therapy showed a high intracranial objective response rate in patients who had not received radiotherapy and had acceptable safety profiles.
Article
Health Care Sciences & Services
Sreeram Ramagopalan, Riccardo Pisoni, Aleksandr Zenin, Lokendra Singh Rathore, Joshua Ray, Cormac Sammon
Summary: The study compared the effectiveness of T-DM1 and lapatinib plus capecitabine as second-line treatment in HER2+ metastatic breast cancer patients. Results showed that overall survival was longer in patients treated with T-DM1, supporting its use as a treatment option.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
(2021)
Article
Oncology
B. Xu, T. Sun, Q. Zhang, P. Zhang, Z. Yuan, Z. Jiang, X. Wang, S. Cui, Y. Teng, X-C Hu, J. Yang, H. Pan, Z. Tong, H. Li, Q. Yao, Y. Wang, Y. Yin, P. Sun, H. Zheng, J. Cheng, J. Lu, B. Zhang, C. Geng, J. Liu, K. Shen, S. Yu, L. Tang, R. Qiu
Summary: The combination therapy of utidelone plus capecitabine significantly improved overall survival, progression-free survival, and overall response rate in heavily-pretreated patients with metastatic breast cancer, with no new safety concerns.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
F. Andre, E. M. Ciruelos, D. Juric, S. Loibl, M. Campone, I. A. Mayer, G. Rubovszky, T. Yamashita, B. Kaufman, Y-S Lu, K. Inoue, Z. Papai, M. Takahashi, F. Ghaznawi, D. Mills, M. Kaper, M. Miller, P. F. Conte, H. Iwata, H. S. Rugo
Summary: The study confirmed a certain efficacy in overall survival when alpelisib was added to fulvestrant treatment in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer, prolonging the median survival time.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Mira Goldberg, Jidapa Bridhikitti, Atif J. Khan, Paul McGale, Timothy J. Whelan
Summary: This meta-analysis evaluated the effectiveness of partial breast irradiation (PBI) compared with whole breast irradiation (WBI) in patients with breast cancer. The results showed that WBI was more effective than PBI overall, but the effectiveness of PBI varied depending on the technique used. Multicatheter brachytherapy or external beam RT with CT planning may be suitable options for women considering PBI, although the absolute difference in outcomes between groups was very small.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Justin Lee, Nhu Tram Nguyen, James Wright, Ka-Kit David Yeung, Stephen Sagar, Do-Hoon Kim, Orest Ostapiak, Lilian Doerwald-Munoz, Timothy Whelan
Summary: This study aims to evaluate the response rates to SBRT in older age patients with locally advanced HNSCC. It suggests that SBRT may offer a shorter and more effective treatment compared to the current standard of care palliative regimens.
Article
Oncology
Mira Goldberg, Sameer Parpia, Eileen Rakovitch, Lynn Chang, Julie Bowen, Himanshu Lukka, Francisco Perera, Anthony Fyles, James Wright, Jonathan Sussman, Timothy Whelan
Summary: The purpose of this study was to evaluate the long-term local and distant recurrence rates in patients with T1mi breast cancer who underwent breast conserving surgery compared to those with T1a-2 disease who received whole breast irradiation. The results showed that patients with T1mi had a higher risk of local recurrence, but overall survival rates were good. Future research should explore wider local excision and higher radiation doses to optimize local control for microinvasive breast cancer.
Review
Oncology
Miguel Martin, Eva Carrasco, Alvaro Rodriguez-Lescure, Raquel Andres, Sonia Servitja, Antonio Anton, Manuel Ruiz-Borrego, Begona Bermejo, Angel Guerrero, Manuel Ramos, Ana Santaballa, Montserrat Munoz, Josefina Cruz, Sara Lopez-Tarruella, Jose I. I. Chacon, Isabel Alvarez, Purificacion Martinez, Juan J. Miralles, Oscar Polonio, Carlos Jara, David Aguiar-Bujanda
Summary: This study analyzed the long-term outcomes of patients similar to the monarchE trial to evaluate the potential benefit of abemaciclib. The results indicated the need for new therapies to improve survival rates for these patients.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Dawn L. L. Hershman, Bingshu E. E. Chen, Claire Sathe, Wendy R. R. Parulekar, Julie Lemieux, Jennifer A. A. Ligibel, Karen A. A. Gelmon, Timothy J. J. Whelan, Pamela J. J. Goodwin
Summary: This study analyzed the adherence and discontinuation rates of metformin and endocrine therapy (ET) among early-stage breast cancer patients. It found that adherence to metformin was low, while adherence to ET was good. Attention should be paid to the association between drug toxicity and adherence to improve patient medication adherence.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Letter
Oncology
M. Goldberg, P. McGale, T. J. Whelan
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Multidisciplinary Sciences
Seong-Hwan Jun, Hosein Toosi, Jeff Mold, Camilla Engblom, Xinsong Chen, Ciara O'Flanagan, Michael Hagemann-Jensen, Rickard Sandberg, Samuel Aparicio, Johan Hartman, Andrew Roth, Jens Lagergren
Summary: Functional characterization of cancer clones is important for understanding cancer's evolutionary mechanisms. The authors introduce PhylEx, a method that combines bulk genomics and single-cell RNA sequencing data to reconstruct clonal trees and identify clones. PhylEx outperforms other methods and allows for accurate inference of clonal trees and analysis of cancer.
NATURE COMMUNICATIONS
(2023)
Article
Cell Biology
Torsten O. Nielsen, Samuel C. Y. Leung, Nazia Riaz, Anna M. Mulligan, Zuzana Kos, Anita Bane, Timothy J. Whelan
Summary: The LUMINA trial showed that in women aged 55 and above with low-risk luminal A breast cancer, very low local recurrence rate was observed when treated with breast-conserving surgery and endocrine therapy, supporting the safe omission of radiation. Ki67 is a practical, reproducible, and inexpensive biomarker that can identify low-risk luminal A breast cancers as potential candidates for radiation de-escalation.
Article
Multidisciplinary Sciences
Nicholas Ceglia, Zachary Sethna, Samuel S. Freeman, Florian Uhlitz, Viktoria Bojilova, Nicole Rusk, Bharat Burman, Andrew Chow, Sohrab Salehi, Farhia Kabeer, Samuel Aparicio, Benjamin D. Greenbaum, Sohrab P. Shah, Andrew McPherson
Summary: To decipher individual cell phenotypes, high dimensional single-cell RNA sequencing is required. GeneVector is a scalable framework that uses gene co-expression to perform dimensionality reduction, allowing for the identification of transcriptional programs and cell type classification. GeneVector has been shown to capture phenotype-specific pathways and identify pathway variation in response to treatment.
NATURE COMMUNICATIONS
(2023)
Article
Cell Biology
Aurora Gomez-Vecino, Roberto Corchado-Cobos, Adrian Blanco-Gomez, Natalia Garcia-Sancha, Sonia Castillo-Lluva, Ana Martin-Garcia, Marina Mendiburu-Elicabe, Carlos Prieto, Sara Ruiz-Pinto, Guillermo Pita, Alejandro Velasco-Ruiz, Carmen Patino-Alonso, Purificacion Galindo-Villardon, Maria Linarejos Vera-Pedrosa, Jose Jalife, Jian-Hua Mao, Guillermo Macias de Plasencia, Andres Castellanos-Martin, Maria del Mar Saez-Freire, Susana Fraile-Martin, Telmo Rodrigues-Teixeira, Carmen Garcia-Macias, Julie Milena Galvis-Jimenez, Asuncion Garcia-Sanchez, Maria Isidoro-Garcia, Manuel Fuentes, Maria Begona Garcia-Cenador, Francisco Javier Garcia-Criado, Juan Luis Garcia-Hernandez, Maria Angeles Hernandez-Garcia, Juan Jesus Cruz-Hernandez, Cesar Augusto Rodriguez-Sanchez, Alejandro Martin Garcia-Sancho, Estefania Perez-Lopez, Antonio Perez-Martinez, Federico Gutierrez-Larraya, Antonio J. Carton, Jose Angel Garcia-Saenz, Ana Patino-Garcia, Miguel Martin, Teresa Alonso-Gordoa, Christof Vulsteke, Lieselot Croes, Sigrid Hatse, Thomas Van Brussel, Diether Lambrechts, Hans Wildiers, Hang Chang, Marina Holgado-Madruga, Anna Gonzalez-Neira, Pedro L. Sanchez, Jesu Perez Losada
Summary: Cardiotoxicity due to anthracyclines (CDA) affects cancer patients, and identifying individuals at risk is challenging. In this study, the authors investigated intermediate molecular phenotypes (IMPs) associated with myocardial damage to determine CDA susceptibility. By analyzing a mouse cohort treated with doxorubicin and docetaxel, they identified genetic markers linked to IMPs and CDA. These markers were also found to be associated with CDA in cancer patients, highlighting their potential as predictive factors. Additionally, genetic risk scores were generated using machine-learning regression to personalize patient management.
Review
Oncology
M. Chadha, J. White, S. M. Swain, E. Rakovitch, R. Jagsi, T. Whelan, J. A. Sparano
Summary: Older women are underrepresented in breast cancer clinical trials, and treatment guidelines are primarily based on studies in younger women. Omission of breast radiation therapy is associated with increased local relapse, but the risk of distant relapse in women aged 70 and above is very low. The incremental benefit of endocrine therapy in decreasing distant relapse rate and improving disease-free survival in older patients with low-risk breast cancer is unclear. Integration of molecular genomic assays in diagnosis and treatment may optimize risk-tailored adjuvant therapies, allowing for treatment de-escalation in older women with early-stage breast cancer. The lack of risk-specific adjuvant therapy guidelines highlights the need for prospective trials to inform optimal treatment selection, including the possibility of omitting adjuvant endocrine therapy in older women with low-risk breast cancer.
Meeting Abstract
Oncology
C. H. D. Wu, M. Wierzbicki, S. Parpia, V. Kundapur, A. Bujold, E. J. Filion, H. Lau, S. Faria, N. Ahmed, N. Leong, G. Okawara, K. J. Hirmiz, T. E. Owen, A. V. Louie, J. Wright, T. J. Whelan, A. Swaminath
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Multidisciplinary Sciences
Yi Cui, Gaojie Yang, Daniel R. Goodwin, Ciara H. O'Flanagan, Anubhav Sinha, Chi Zhang, Kristina E. Kitko, Tay Won Shin, Demian Park, Samuel Aparicio, Edward S. Boyden
Summary: Expansion microscopy (ExM) enlarges specimens physically for nanoimaging on standard light microscopes. The multifunctional anchor simplifies ExM protocols, reduces cost, and enables the preservation and visualization of RNA transcripts, proteins, and other biomolecular species.
Article
Oncology
Diogo Martins-Branco, Marie Kassapian, Veronique Debien, Rafael Caparica, Daniel Eiger, Urania Dafni, Charitini Andriakopoulou, Sarra El-Abed, Susan L. Ellard, Miguel Izquierdo, Malou Vicente, Saranya Chumsri, Martine Piccart-Gebhart, Alvaro Moreno-Aspitia, Ann Soegaard Knop, Janine Lombard, Evandro de Azambuja
Summary: This study aimed to assess the impact of erythropoiesis-stimulating agents (ESA) on the outcomes of patients with HER2-positive early breast cancer (EBC). The results showed that ESA administration did not have a negative impact on disease-free survival and overall survival, and the incidence of adverse events was low in patients receiving ESA treatment.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Multidisciplinary Sciences
Ha-Linh Nguyen, Tatjana Geukens, Marion Maetens, Samuel Aparicio, Ayse Bassez, Ake Borg, Jane Brock, Annegien Broeks, Carlos Caldas, Fatima Cardoso, Maxim De Schepper, Mauro Delorenzi, Caroline A. Drukker, Annuska M. Glas, Andrew R. Green, Edoardo Isnaldi, Jorunn Eyfjoro, Hazem Khout, Stian Knappskog, Savitri Krishnamurthy, Sunil R. Lakhani, Anita Langerod, John W. M. Martens, Amy E. McCart Reed, Leigh Murphy, Stefan Naulaerts, Serena Nik-Zainal, Ines Nevelsteen, Patrick Neven, Martine Piccart, Coralie Poncet, Kevin Punie, Colin Purdie, Emad A. Rakha, Andrea Richardson, Emiel Rutgers, Anne Vincent-Salomon, Peter T. Simpson, Marjanka K. Schmidt, Christos Sotiriou, Paul N. Span, Kiat Tee Benita Tan, Alastair Thompson, Stefania Tommasi, Karen Van Baelen, Marc Van de Vijver, Steven Van Laere, Laura van't Veer, Giuseppe Viale, Alain Viari, Hanne Vos, Anke T. Witteveen, Hans Wildiers, Giuseppe Floris, Abhishek D. Garg, Ann Smeets, Diether Lambrechts, Elia Biganzoli, Francois Richard, Christine Desmedt
Summary: Obesity is associated with an increased risk of developing breast cancer and worse prognosis in breast cancer patients. This study investigates the biological differences in untreated primary breast cancer according to patients' body mass index (BMI). The study finds several genomic alterations that are differentially prevalent in overweight or obese patients compared to lean patients. It also reveals an elevated and unresolved inflammation of the breast cancer tumor microenvironment associated with obesity. The findings suggest that patient adiposity may play a significant role in the heterogeneity of breast cancer and should be considered for tailored treatment.
NATURE COMMUNICATIONS
(2023)